The orally bioavailable C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with radioisotope and potential antineoplastic activities. 14C BMS-275183 binds to tubulin and inhibits microtubule disassembly, which may result in cell cycle arrest at the G2/M phase and inhibition of cell division, and subsequently cell death. This agent may be useful for treating multi-drug resistant (MDR) tumors because it does not appear to be a substrate for P-glycoprotein.
Learn more about 14C BMS-275183
- Dailymed label info
- Scientific articles
- Drug portal 14C BMS-275183
- toxicity info on 14C BMS-275183
- FDA 14C BMS-275183